SunWay Biotech Co., LTD. (TPEX:1271)
78.30
-0.60 (-0.77%)
Aug 12, 2025, 1:58 PM CST
Satixfy Communications Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 293.71 | 362.19 | 123.57 | 346.44 | 295.34 | Upgrade |
Cash & Short-Term Investments | 293.71 | 362.19 | 123.57 | 346.44 | 295.34 | Upgrade |
Cash Growth | -18.91% | 193.11% | -64.33% | 17.30% | 351.96% | Upgrade |
Accounts Receivable | 298.3 | 266.47 | 170.66 | 102.45 | 45.97 | Upgrade |
Other Receivables | - | - | - | - | 0.13 | Upgrade |
Receivables | 298.3 | 266.47 | 206.91 | 102.45 | 46.1 | Upgrade |
Inventory | 210.03 | 170.23 | 94 | 76.91 | 90.01 | Upgrade |
Prepaid Expenses | 15.46 | 9.13 | 12.26 | 2.84 | 2.93 | Upgrade |
Other Current Assets | 7.99 | 4.74 | 3.83 | - | - | Upgrade |
Total Current Assets | 825.48 | 812.76 | 440.56 | 528.63 | 434.38 | Upgrade |
Property, Plant & Equipment | 337.12 | 319.45 | 5.43 | 48.64 | 15.3 | Upgrade |
Long-Term Investments | 12.97 | 7.76 | - | 5.34 | 4.4 | Upgrade |
Goodwill | 2,027 | 2,027 | - | - | - | Upgrade |
Other Intangible Assets | 392.16 | 429.39 | 16.85 | 11.68 | 12.83 | Upgrade |
Long-Term Deferred Tax Assets | 4.22 | 6.97 | 5.92 | - | - | Upgrade |
Other Long-Term Assets | 193.76 | 136.53 | 9.47 | 13.41 | 44.25 | Upgrade |
Total Assets | 3,792 | 3,740 | 478.23 | 607.7 | 511.15 | Upgrade |
Accounts Payable | 51.54 | 35.72 | 57.96 | 18.59 | 15.57 | Upgrade |
Accrued Expenses | - | - | - | 29.87 | 18.82 | Upgrade |
Short-Term Debt | - | 7.51 | 65.56 | - | - | Upgrade |
Current Portion of Leases | 17.04 | 31.55 | 2.4 | 2.51 | 2.43 | Upgrade |
Current Income Taxes Payable | 24.63 | 18.43 | 7.39 | 0.49 | - | Upgrade |
Current Unearned Revenue | 13.65 | 15.89 | 14.95 | 0.84 | 3.95 | Upgrade |
Other Current Liabilities | 116.57 | 94.3 | 38.84 | 8.34 | 5.76 | Upgrade |
Total Current Liabilities | 223.44 | 203.4 | 187.1 | 60.65 | 46.53 | Upgrade |
Long-Term Leases | 226.95 | 248.3 | 3.05 | - | - | Upgrade |
Long-Term Deferred Tax Liabilities | 75.08 | 82.24 | - | - | - | Upgrade |
Other Long-Term Liabilities | 1.66 | 3.28 | - | - | - | Upgrade |
Total Liabilities | 527.13 | 537.21 | 190.14 | 60.65 | 46.53 | Upgrade |
Common Stock | 603.89 | 593.89 | 209.19 | 331.35 | 329.95 | Upgrade |
Additional Paid-In Capital | 2,524 | 2,555 | - | 29.08 | 39.23 | Upgrade |
Retained Earnings | 131.06 | 51.09 | 32.82 | 195.83 | 106.55 | Upgrade |
Comprehensive Income & Other | 3.36 | -0.68 | 46.08 | -12.6 | -13.54 | Upgrade |
Total Common Equity | 3,263 | 3,199 | 288.09 | 543.66 | 462.19 | Upgrade |
Minority Interest | 2.6 | 2.89 | - | 3.39 | 2.44 | Upgrade |
Shareholders' Equity | 3,265 | 3,202 | 288.09 | 547.05 | 464.62 | Upgrade |
Total Liabilities & Equity | 3,792 | 3,740 | 478.23 | 607.7 | 511.15 | Upgrade |
Total Debt | 243.99 | 287.35 | 71.01 | 2.51 | 2.43 | Upgrade |
Net Cash (Debt) | 49.71 | 74.84 | 52.57 | 343.93 | 292.91 | Upgrade |
Net Cash Growth | -33.57% | 42.37% | -84.72% | 17.42% | 446.19% | Upgrade |
Net Cash Per Share | 0.82 | 2.44 | 2.60 | 10.01 | 9.02 | Upgrade |
Filing Date Shares Outstanding | 60.39 | 60.39 | 34.11 | 33.69 | 33.55 | Upgrade |
Total Common Shares Outstanding | 60.39 | 60.39 | 34.11 | 33.69 | 33.55 | Upgrade |
Working Capital | 602.04 | 609.36 | 253.47 | 467.99 | 387.85 | Upgrade |
Book Value Per Share | 54.03 | 52.98 | 8.44 | 16.14 | 13.78 | Upgrade |
Tangible Book Value | 843.81 | 743.36 | 271.24 | 531.98 | 449.36 | Upgrade |
Tangible Book Value Per Share | 13.97 | 12.31 | 7.95 | 15.79 | 13.39 | Upgrade |
Machinery | 100.91 | 102.56 | 1.78 | 129.24 | 88.42 | Upgrade |
Construction In Progress | 57.04 | 31.9 | - | - | - | Upgrade |
Leasehold Improvements | 58.95 | 25.58 | - | 23.19 | 23.76 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.